Latest Breaking News On - Bluejay therapeutics - Page 1 : comparemela.com

InnovationRx: Battle Of The AI Medical Scribes

InnovationRx: Battle Of The AI Medical Scribes
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.

United statesGlen tullmanManny krakarisMian shakilNovo nordiskBrixton biosciencesView researchUnitedhealth groupAi bot demystifies health insuranceGrand view researchBluejay therapeuticsMetaphore biotechnologiesSands capitalRetro biosciencesMultiply labsHealth group

Lycia Therapeutics Lands $106M for Protein Degraders That Treat Autoimmune & Inflammatory Diseases

Lycia Therapeutics Lands $106M for Protein Degraders That Treat Autoimmune & Inflammatory Diseases
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomLa jollaAl iskandariyahMarshall waceDavid bakerZenas biopharmaEli lillyAsher biotherapeuticsBridgebio pharmaVersant inception sciences discovery engineFranklin templetonDeciphera pharmaceuticalsUniversity of dundeeFrazier life sciencesBristol myers squibb

Bluejay Therapeutics Raises $182M in Series C Financing

Bluejay Therapeutics Raises $182M in Series C Financing
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.

New zealand generalNew zealandDaniel estesFrazier life sciencesNovo holdingsBluejay therapeuticsSan mateoWellington managementRivervest venture partnersOctagon capitalArkin bio venturesGeneral partnerKeting chu

Exicure, Inc and Bluejay Therapeutics Inc Enter into a Patent License Agreement to Develop Cavroto

CHICAGO (BUSINESS WIRE) Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. (".

Paul kangBluejay therapeutics incExicure incBluejay therapeuticsChief executive officer

Exicure and Bluejay sign hepatitis treatment development deal

Exicure and Bluejay Therapeutics have reached a patent licencing agreement for the development of cavrotolimod as a potential hepatitis treatment.

Paul kangInnopinnacle internationalArkin bio venturesRivervest venture partnersYonjin capitalOctagon capitalBluejay therapeutics